Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Webinar w $ATE CEO Dan Legault - Mon Nov 21 @ 4:15PM ET

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Nov 17, 2022 7:00pm

154 Views

Post# 35108904

RE:Webinar w $ATE CEO Dan Legault - Mon Nov 21 @ 4:15PM ET

bmreed wrote:
Webinar - Antibe Therapeutics $ATE w/ CEO Dan Legault

Mon, November 21 at 4:15pm ET / 1:15pm PT

Q&A with Radius Research

Register Here - https://us02web.zoom.us/webinar/register/5216686324941/WN_NEICOjy7TOCAAlEzN3441w

Brings up a good question ... is it Q&A with or without the Q4 IBD update ?

If it's without the IBD update, why not wait unitl we get the update, until we get the presentation ... then host a Q&A on all this new stuff too ?

Guess we still have Friday and Monday to get an IBD update ... hahaha !
I wouldn't put money on it though !!!!

<< Previous

Bullboard Posts

Next >>

Cannara reports record growth and profitability in Q4 2023